The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
3d
HealthDay on MSNFDA Approves More Broadly Protective Meningococcal VaccineThe U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
A panel of experts advising the U.S. Centers for Disease Control and Prevention on vaccines will not convene for its February ...
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
A CDC vaccine advisory committee meeting scheduled for next week has been postponed. It was the first vaccine meeting since ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
16h
Medpage Today on MSNReport: RFK Jr. Planning to Remove Advisors on Vaccine CommitteeHHS Secretary Robert F. Kennedy Jr. appears to be planning major changes to the way his department oversees vaccines, media ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results